Adalimumab-associated optic neuritis

Journal of the Neurological Sciences

Volumn 244, Issue 1-2, 2006, Pages 133-136

  Chung, Jacob H ^a   Van Stavern, Gregory P ^b   Frohman, Larry P ^a   Turbin, Roger E ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Adalimumab; Enbrel; Etanercept; Humira; Infliximab; Optic neuritis; Remicade; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ATENOLOL; ETANERCEPT; FOLIC ACID; INFLIXIMAB; METFORMIN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PAROXETINE; PREDNISONE; RISPERIDONE; SIMVASTATIN; STEROID;

ADULT; ARTICLE; CASE REPORT; DEMYELINATING DISEASE; ENTERITIS; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUPIL DISEASE; RHEUMATOID ARTHRITIS; SCOTOMA; TREATMENT FAILURE; VISUAL ACUITY; VISUAL DISORDER;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; OPTIC NERVE; OPTIC NEURITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VISION, LOW;

EID: 33646089875     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.01.012     Document Type: Article

References (13)

1. Sharief M.K., and Hentges R. Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325 (1991) 467-472
2. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
3. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 (2001) 2862-2869
4. Lenercept M.S., and Study Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53 (1999) 457-465
5. Strong B.Y., Erny B.C., Herzenberg H., and Razzeca K.J. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease. Ann Intern Med 140 (2004) 677-678
6. Foroozan R., Buono L.M., Sergott R.C., and Savino P.J. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120 (2002) 985-987
7. Iuorno J.D., Kolostyak K.P., and Mejico L.J. Therapies with potential toxicity of neuro-ophthalmic interest. Curr Opin Ophthalmol 6 (2003) 339-343
8. ten Tusscher M.P., Jacobs P.J., Busch M.J., de Graaf L., and Diemont W.L. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 326 (2003) 579
9. Humira package insert.
10. Abbott Laboratories, data on file.
11. Selmaj K., Raine C.S., and Cross A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30 (1991) 694-700
12. Remicade package insert.
13. Robinson W.H., Genovese M.C., and Moreland L.W. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum 44 (2001) 1977-1983